Cargando…
Assessing the Immunogenicity of Biopharmaceuticals
Biopharmaceuticals have the potential to raise an immunogenic response in treated individuals, which may impact the efficacy and safety profile of these drugs. As a result, it is essential to evaluate immunogenicity throughout the different phases of the clinical development of a biopharmaceutical,...
Autores principales: | Pineda, Carlos, Castañeda Hernández, Gilberto, Jacobs, Ira A., Alvarez, Daniel F., Carini, Claudio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4875071/ https://www.ncbi.nlm.nih.gov/pubmed/27097915 http://dx.doi.org/10.1007/s40259-016-0174-5 |
Ejemplares similares
-
10(th) European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals
por: Tourdot, S., et al.
Publicado: (2020) -
Regulatory and strategic considerations for addressing immunogenicity and related responses in biopharmaceutical development programs
por: Vandivort, Tyler C., et al.
Publicado: (2020) -
Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium
por: Rup, B, et al.
Publicado: (2015) -
The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review
por: Barbier, Liese, et al.
Publicado: (2020) -
Determination of immunogenic proteins in biopharmaceuticals by UHPLC–MS amino acid analysis
por: Piestansky, Juraj, et al.
Publicado: (2019)